Member Info for Mars1

Grant applications close 20th January
https://apply-for-innovation-funding.service.gov.uk/competition/search?innovationAreaId=&keywords=smart

Not keeping up with bb at moment so apologies if covered. Plenty of DHSC tenders about to kick in for antibody tests. So sales are coming. What is the reason. Hospital staff cannot treat patients without certainty immunity still exists. So regular testing of staff, how regular, quarterly maybe. But it will have to be done. Will other employers do the same? At the moment hospital staff have twice weekly antigen tests.

Korda the top group of pictures if you look at the top right picture it clearly says CD4 products so that looks as though they are all complete tests awaiting delivery. No company will mix completed products with raw materials awaiting production. Boom!

Boxes not addressed ODX they are addressed Mologic

Doom do not need an antigen test if vaccinated it will be an antibody test to confirm vaccine

Global demand will be huge drive to limit the virus travelling. Why restrict movement within a country and allow untested travellers within the community it is going to become a way of life

We have already seen France request antigen tests for lorry drivers, so it will be antigen for the unvaccinated and antibody for vaccinated.

Chugg agree sample testing will be needed for ongoing efficacy, however freedom will be the big seller as more vaccinated countries will require an antibody test before travel.

Is the one thing that brings the abc test into play

You can see businesses wanting staff vaccinated so they can get economy moving, travel with antibody tests

Do not need MRHA home approval for airport antibody tests so you can travel. More vaccinated the bigger the demand

There is no freedom certificate if you have the vaccine, go on holiday or to sport event only way to show you are free take an antibody test

From ODX RNS dated 30th Nov
“ . The AbC-19™ Rapid test was specifically developed as a companion diagnostic test, alongside the Oxford University and AstraZeneca COVID-19 vaccine programme. The Oxford vaccine triggers the body to produce trimeric spike protein neutralising antibodies and the AbC-19™ Rapid test is specifically designed to detect those antibodies. The Company therefore welcomes the recent news confirming efficacy of the Oxford vaccine and believes this will support increased demand.



The UK-RTC believes that the AbC-19™ Rapid test can be deployed at scale across populations to aid policymakers, healthcare systems, the scientific community and the public at large by:



· Clearly showing the extent of COVID-19 infection and its spread through communities (i.e. surveillance)

· Enabling researchers to understand whether people are developing immunity

· Playing a vital role in assessing initial immune response to new vaccines and in determining where follow-up or booster campaigns may be needed”

Vascular the vaccine is seeking FDA approval will help with a US test

Starbright thanks but you would know then the EPS is the E in p/e ratio

Bakedbean yes and that ignores the other earnings from CD4 and food intolerance tests

Takingiteasy yes agree will be sometime yet before COVID testing comes to an end. Govt already stated they want to expand the type of diagnostic tests for other diseases so it will evolve to become a preventative tool. What of course is of concern is that this will not be the last of this type of virus.
One thing OFX will be cash rich, within 12 months will hold more than its current Mcap.

Star bright definition of p/earaches for your info is based on profit
“ Earnings per share (EPS) is a figure describing a public company's profit per outstanding share of stock, calculated on a quarterly or annual basis. EPS is arrived at by taking a company's quarterly or annual net income and dividing by the number of its shares of stock outstanding.”

Takingiteasy rather short term p/e as only forward to Jan and static numbers annualised, if forecast numbers taken for year of course it will be a lot higher, however market does not seem able to look beyond the end of its nose at the moment

So ODX tweeted a chart showing 500k tests a week in Dec and 900k in Feb with 2m a week in April. If that means 700k in Jan then...
200x80p= 160k (abc)
700x£2= £1.4m (Mologic)
£1.54mx50weeks= £77m profit
P/e 3 =£231m to p/e 5= £385m. £1.5 to £2.2